ABIONYX PHARMA SA (ABNX.PA) Stock Price, Forecast & Analysis

EPA:ABNX • FR0012616852

3.585 EUR
-0.02 (-0.42%)
Last: Feb 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership

ABNX.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap127.30M
Revenue(TTM)4.33M
Net Income(TTM)-4.60M
Shares35.51M
Float21.72M
52 Week High5.29
52 Week Low1.09
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.14
PEN/A
Fwd PEN/A
Earnings (Next)03-12
IPO2015-03-30
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
ABNX.PA short term performance overview.The bars show the price performance of ABNX.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80

ABNX.PA long term performance overview.The bars show the price performance of ABNX.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200

The current stock price of ABNX.PA is 3.585 EUR. In the past month the price decreased by -3.63%. In the past year, price increased by 193.85%.

ABIONYX PHARMA SA / ABNX Daily stock chart

ABNX.PA Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to ABNX.PA. When comparing the yearly performance of all stocks, ABNX.PA is one of the better performing stocks in the market, outperforming 98.33% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
ABNX.PA Full Technical Analysis Report

ABNX.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ABNX.PA. The financial health of ABNX.PA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ABNX.PA Full Fundamental Analysis Report

ABNX.PA Financial Highlights

Over the last trailing twelve months ABNX.PA reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS decreased by -28.06% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -35.18%
ROE -83.55%
Debt/Equity 0.59
Chartmill High Growth Momentum
EPS Q2Q%-2.64%
Sales Q2Q%-9.6%
EPS 1Y (TTM)-28.06%
Revenue 1Y (TTM)-10.91%
ABNX.PA financials

ABNX.PA Forecast & Estimates

8 analysts have analysed ABNX.PA and the average price target is 10.71 EUR. This implies a price increase of 198.74% is expected in the next year compared to the current price of 3.585.

For the next year, analysts expect an EPS growth of -34.37% and a revenue growth -1.09% for ABNX.PA


Analysts
Analysts85
Price Target10.71 (198.74%)
EPS Next Y-34.37%
Revenue Next Year-1.09%
ABNX.PA Analyst EstimatesABNX.PA Analyst Ratings

ABNX.PA Ownership

Ownership
Inst Owners4.38%
Ins Owners38.37%
Short Float %N/A
Short RatioN/A
ABNX.PA Ownership

ABNX.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ARGX ARGENX SE28.1143.863B
1AE ARGENX SE27.9943.776B
22UA BIONTECH SE-ADR N/A21.869B
ABVX ABIVAX SA N/A8.398B
2X1 ABIVAX SA N/A8.382B
GXE GALAPAGOS NV N/A1.882B
GLPG GALAPAGOS NV N/A1.869B
6IV INVENTIVA SA N/A1.112B
IVA INVENTIVA SA N/A1.092B
NANO NANOBIOTIX N/A1.006B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges

About ABNX.PA

Company Profile

ABNX logo image ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie and currently employs 51 full-time employees. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.

Company Info

ABIONYX PHARMA SA

Bat. D 33-43 Avenue Georges Pompidou

Balma OCCITANIE FR

Employees: 51

ABNX Company Website

ABNX Investor Relations

Phone: 33562249706

ABIONYX PHARMA SA / ABNX.PA FAQ

What does ABIONYX PHARMA SA do?

ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie and currently employs 51 full-time employees. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.


What is the current price of ABNX stock?

The current stock price of ABNX.PA is 3.585 EUR. The price decreased by -0.42% in the last trading session.


Does ABNX stock pay dividends?

ABNX.PA does not pay a dividend.


What is the ChartMill rating of ABIONYX PHARMA SA stock?

ABNX.PA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the upcoming earnings date for ABIONYX PHARMA SA?

ABIONYX PHARMA SA (ABNX.PA) will report earnings on 2026-03-12, after the market close.


Can you provide the ownership details for ABNX stock?

You can find the ownership structure of ABIONYX PHARMA SA (ABNX.PA) on the Ownership tab.